HK1216236A1 - 給藥於眼後段的眼用製劑 - Google Patents

給藥於眼後段的眼用製劑

Info

Publication number
HK1216236A1
HK1216236A1 HK16104118.1A HK16104118A HK1216236A1 HK 1216236 A1 HK1216236 A1 HK 1216236A1 HK 16104118 A HK16104118 A HK 16104118A HK 1216236 A1 HK1216236 A1 HK 1216236A1
Authority
HK
Hong Kong
Prior art keywords
eye
drug
delivery
posterior segment
ocular formulations
Prior art date
Application number
HK16104118.1A
Other languages
English (en)
Inventor
David P Bingaman
Paul G Chaney
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of HK1216236A1 publication Critical patent/HK1216236A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16104118.1A 2013-03-14 2016-04-11 給藥於眼後段的眼用製劑 HK1216236A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784681P 2013-03-14 2013-03-14
PCT/US2014/027589 WO2014152661A1 (en) 2013-03-14 2014-03-14 Ocular formulations for drug-delivery to the posterior segment of the eye

Publications (1)

Publication Number Publication Date
HK1216236A1 true HK1216236A1 (zh) 2016-10-28

Family

ID=50625096

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104118.1A HK1216236A1 (zh) 2013-03-14 2016-04-11 給藥於眼後段的眼用製劑

Country Status (23)

Country Link
US (7) US10092549B2 (zh)
EP (2) EP2968650B1 (zh)
JP (3) JP6542193B2 (zh)
KR (2) KR20210132205A (zh)
CN (2) CN111789814B (zh)
AU (3) AU2014239252B2 (zh)
BR (1) BR112015021334B1 (zh)
CA (1) CA2900840C (zh)
DK (1) DK2968650T3 (zh)
ES (1) ES2710152T3 (zh)
HK (1) HK1216236A1 (zh)
HU (1) HUE042528T2 (zh)
IL (2) IL240510B (zh)
MX (1) MX360888B (zh)
PH (2) PH12015501938A1 (zh)
PL (1) PL2968650T3 (zh)
PT (1) PT2968650T (zh)
RU (2) RU2768489C2 (zh)
SA (1) SA516380321B1 (zh)
SG (2) SG10201710928PA (zh)
TR (1) TR201901462T4 (zh)
WO (1) WO2014152661A1 (zh)
ZA (2) ZA201505447B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102171897B1 (ko) 2012-09-12 2020-11-02 노바리크 게엠베하 부분불소화 알칸 조성물
EP3193867B1 (en) * 2014-09-17 2021-01-20 PanOptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
CN111743882A (zh) 2015-09-30 2020-10-09 诺瓦利克有限责任公司 半氟化化合物和其组合物
US10155360B2 (en) 2016-03-11 2018-12-18 Georgia-Pacific Gypsum Llc Gypsum panels, systems, and methods
KR102351816B1 (ko) * 2017-04-21 2022-01-17 노바리크 게엠베하 요오드 조성물
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AT522609B1 (de) 2019-05-28 2022-06-15 Miba Frictec Gmbh Reibvorrichtung
TW202308703A (zh) 2021-05-03 2023-03-01 美商亞維拉治療公司 用於降解免疫球蛋白及其他蛋白質之有效asgpr結合化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
HUP0202745A2 (hu) * 1999-09-06 2003-01-28 Ono Pharmaceutical Co., Ltd. Profilaktikus és terápiás szerek szembetegségek kezelésére
OA12532A (en) * 2000-11-28 2006-06-02 Pfizer Prod Inc Salts of a isothiazole-4-carboxamide and their useas anti-hyperproliferation agents.
JP4511352B2 (ja) * 2002-07-25 2010-07-28 ファイザー・インク 抗癌薬として有用なイソチアゾール誘導体
CN1533553A (zh) * 2002-08-29 2004-09-29 ��˹��ķ��ʽ���� 视觉辅助网络服务器,视觉辅助网络系统,视觉辅助方法,视觉辅助系统,视觉缺陷告知系统,视觉缺陷告知程序,视觉缺陷告知方法,色彩辨别辅助系统,色彩辨别辅助程序,以及色彩辨别辅助方法
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
US7483533B2 (en) * 2004-08-05 2009-01-27 King Fahd University Of Petroleum Elliptic polynomial cryptography with multi x-coordinates embedding
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
AU2005304034B2 (en) * 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
NZ563984A (en) 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
JP2007011785A (ja) * 2005-06-30 2007-01-18 Toshiba Corp 情報処理装置、およびタッチパネルの振動制御方法
JP2007012937A (ja) * 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ES2351358T3 (es) * 2005-10-10 2011-02-03 Novagali Pharma S.A. Emulsiones oftálmicas que contienen prostaglandinas.
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2008103613A2 (en) * 2007-02-22 2008-08-28 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
CN101848715A (zh) * 2007-08-09 2010-09-29 千寿制药株式会社 含吡诺克辛的二液性滴眼剂
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
JP2012250918A (ja) * 2011-05-31 2012-12-20 Rohto Pharmaceutical Co Ltd ニューキノロン剤含有水性組成物
CA2865132A1 (en) 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent

Also Published As

Publication number Publication date
TR201901462T4 (tr) 2019-02-21
KR20210132205A (ko) 2021-11-03
CN105142686B (zh) 2020-04-10
US10307404B1 (en) 2019-06-04
PH12015501938B1 (en) 2016-01-11
MX2015012653A (es) 2016-08-18
PH12015501938A1 (en) 2016-01-11
IL240510A0 (en) 2015-10-29
US20210196690A1 (en) 2021-07-01
RU2768489C2 (ru) 2022-03-24
US20190183864A1 (en) 2019-06-20
US20140303219A1 (en) 2014-10-09
US20160022646A1 (en) 2016-01-28
WO2014152661A1 (en) 2014-09-25
CN105142686A (zh) 2015-12-09
AU2019202857B2 (en) 2021-02-18
EP3520773A1 (en) 2019-08-07
IL276016A (en) 2020-08-31
JP2022009275A (ja) 2022-01-14
SA516380321B1 (ar) 2019-01-16
PT2968650T (pt) 2019-02-12
AU2017210543A1 (en) 2017-08-17
IL276016B (en) 2022-04-01
SG10201710928PA (en) 2018-02-27
ZA201907176B (en) 2022-12-21
SG11201507316UA (en) 2015-10-29
CN111789814B (zh) 2022-07-19
JP2016517427A (ja) 2016-06-16
AU2019202857A1 (en) 2019-05-16
US20190240201A1 (en) 2019-08-08
KR102433489B1 (ko) 2022-08-17
RU2015143898A (ru) 2017-04-19
JP6965308B2 (ja) 2021-11-10
RU2018128980A (ru) 2018-11-05
JP2019167377A (ja) 2019-10-03
MX360888B (es) 2018-11-20
BR112015021334B1 (pt) 2020-04-07
IL240510B (en) 2020-08-31
PH12019501902A1 (en) 2021-03-01
EP2968650A1 (en) 2016-01-20
CN111789814A (zh) 2020-10-20
EP2968650B1 (en) 2019-01-16
US20190247368A1 (en) 2019-08-15
US9446026B2 (en) 2016-09-20
PL2968650T3 (pl) 2019-05-31
CA2900840C (en) 2023-03-28
RU2018128980A3 (zh) 2022-01-11
RU2665953C2 (ru) 2018-09-05
US20160354349A1 (en) 2016-12-08
ZA201505447B (en) 2022-06-29
JP6542193B2 (ja) 2019-07-10
US10092549B2 (en) 2018-10-09
HUE042528T2 (hu) 2019-07-29
AU2014239252A1 (en) 2015-08-13
AU2017210543B2 (en) 2019-01-31
DK2968650T3 (en) 2019-03-11
ES2710152T3 (es) 2019-04-23
KR20150127256A (ko) 2015-11-16
BR112015021334A2 (pt) 2017-07-18
AU2014239252B2 (en) 2017-07-06
CA2900840A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
IL276016B (en) Ocular formulations for administration of drug to the back of the eye
IL267997A (en) Preparations, formulations and methods for treating eye diseases
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
IL244687A0 (en) Epinephrine-based ophthalmic preparations for intraocular administration and methods for their production
EP2928424A4 (en) SYSTEMS AND METHOD FOR MOISTENING EYES DURING EYE OPERATION
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
SG11201506882YA (en) Ophthalmic formulations
HK1221190A1 (zh) 炎症性眼科疾病的局部治療
EP2950782A4 (en) RETARD FORMULATIONS FOR THE TREATMENT OF INTRAOCULAR PRESSURE OR GLAUCOMA
GB2571647B (en) The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation
GB201303131D0 (en) Ocular prosthesis
GB2520410B (en) Digital applanation tonometer
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye
GB201306413D0 (en) The local treatment of ophthalmic diseases